Clinical Trials Logo

Effect of Drug clinical trials

View clinical trials related to Effect of Drug.

Filter by:

NCT ID: NCT05595044 Recruiting - Effect of Drug Clinical Trials

Effect of Vitamin D Therapy in Autism Spectrum Disorder

Start date: October 1, 2020
Phase: Phase 1
Study type: Interventional

The aim of this work is to study the adjuvant effect of vitamin D supplementation on inflammatory marker (IL4) and habilitation outcome in children with Autism Spectrum Disorder in order to evaluate its efficiency as a treatment option based on correction of immune dysfunction.

NCT ID: NCT05482451 Recruiting - Effect of Drug Clinical Trials

Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer

Start date: March 1, 2021
Phase: Early Phase 1
Study type: Interventional

This study is to examine the anticancer activity of the combination therapy with all-trans retinoic acid and nivolumab in patients with chemotherapy-refractory advanced or metastatic pancreatic adenocarcinoma.

NCT ID: NCT05438979 Recruiting - Effect of Drug Clinical Trials

Joint Health Study

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

Natural dietary health supplements that may improve quality of life by relieving joint discomfort have been of increasing interest. Recent studies have demonstrated promising effects of one such supplement - calcium fructoborate (CFB). Preliminary evidence suggests that CFB may reduce joint discomfort, however, few well-powered studies have been conducted to assess the true effects of this supplement. In this study, conducted virtually, we will examine changes in joint discomfort over a 90 day period. Participants will be randomized to receive either 216mg CFB or placebo (i.e., 216mg microcellulose) to take every day for the study period.

NCT ID: NCT05401825 Recruiting - Effect of Drug Clinical Trials

Antenatal COVID 19 Vaccination and Pregnancy Outcomes

Start date: February 18, 2022
Phase:
Study type: Observational

Effect of COVID 19 vaccinations on pregnancy outcomes must be clear and identified to detect their safty

NCT ID: NCT05252429 Recruiting - Effect of Drug Clinical Trials

Docetaxel/Pembrolizumab in Head and Neck Squamous Cell Carcinoma

Start date: July 6, 2022
Phase: Phase 2
Study type: Interventional

Pembrolizumab monotherapy and platinum-based chemotherapy in the combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) have been widely used in daily clinical practice based on the KEYNOTE-048 study. On the other hand, docetaxel is a commonly used antimitotic agent in cancer therapy and might have potent antitumor effect by the immune response. A combination therapy of docetaxel and pembrolizumab might be a promising treatment for R/M HNSCC. The KEYNOTE-048 study showed that pembrolizumab plus platinum and 5-fluorouracil is a tolerable treatment for R/M HNSCC. The main grade 3/4 adverse event of platinum and 5-fluorouracil was myelosuppression such as neutropenia similar to docetaxel in some studies for R/M HNSCC. The safety profile of platinum and 5-fluorouracil is not much different from docetaxel. Therefore, docetaxel/pembrolizumab combination treatment might also be tolerable. The hypothesis of this study is that a combination therapy of docetaxel and pembrolizumab will provide benefit for patients with R/M HNSCC.

NCT ID: NCT05092074 Recruiting - Clinical trials for Hepatitis C Virus Infection

Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection

Start date: October 1, 2021
Phase:
Study type: Observational

The investigators aim to assess the effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) for 12 weeks in hepatitis C virus (HCV)-infected patients who fail to prior NS5A-containing DAA regimens and HCV genotype 1a and 3 patients who fail to prior non-NS5A-containing DAA regimen in Taiwan on a basis of a multicenter observational study.

NCT ID: NCT04960943 Recruiting - Effect of Drug Clinical Trials

Efficacy and Safety of Pyrotinib in HER2 Positive Gastrointestinal Tumors

Start date: February 1, 2020
Phase: Phase 2
Study type: Interventional

Targeting human epidermal factor receptor 2 (HER2) therapy have shown the anti-tumor efficacy in patients with HER2-positive gastrointestinal tumors. Pyrotinib is an irreversible small-molecule receptor tyrosine kinase inhibitor targeting both epidermal growth factor receptor (EGFR) and HER2. This study is designed to evaluate the efficacy and safety of Pyrotinib in patients with HER2 positive gastrointestinal tumors.

NCT ID: NCT04573049 Recruiting - Heart Failure Clinical Trials

The Effectiveness and Safety of Levosimendan in Patients With Severe Aortic Stenosis and Heart Failure Undergoing Transcatheter Aortic Valve Replacement

Start date: September 1, 2020
Phase: Phase 4
Study type: Interventional

A study to evaluate the effectiveness and safety of levosimendan compared with placebo in subjects with severe aortic stenosis and heart failure undergoing transcatheter aortic valve replacement